Working group 1: Shaping the patient contribution to EU policy – drawing on the Clinical Trials and Medical Devices Regulation debates

EPF Conference, 23 May 2013, Dublin

Facilitators: Nicola Bedlington, EPF Executive Director and Kaisa Immonen-Charalambous, EPF Senior Policy Adviser

Rapporteur: Stanimir Hasurdjiev

Workshop agenda

- Overview of the legislation processes in EU and the roles of EPF and its members
- Update on Clinical Trials Legislation
- Update on Medical Devices Legislation

Discussion points (suggestions)

- Critical success factors – the “do’s” (and “don’t’s”)
- Where are the barriers & how to overcome them
- What factors affect patient organisations’ credibility and effectiveness vis-à-vis EU institutions?
- How best to link up effective patient advocacy at national level with EU-level advocacy → effectiveness in the Council?
- Follow-through to ensure patients’ views integrated also in implementation of EU legislation in Member States
- Other …. ?

3 key recommendations to the Plenary

Working group 1: Recommendations

1. Provision of training and support to POs on national level for more effective advocacy
2. National platforms to work with national institutions and to inform EPF of developments – EPF to engage with Council proactively at early stage
3. EPF to prepare “patients document” on each dossier giving clear overview
4. To develop compelling and solid evidence base, credible to all relevant institutions